Clinical Trial Update: Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and dose-expansion study to evaluate the safety of Azer-cel (PBCAR0191) in relapsed/refractory non-Hodgkin lymphoma and relapsed/refract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Azer-cel

Snippet

Sponsor: Imugene Limited | Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING